$RPRX
Royalty Pharma plc

2021 Q3 Form 10-Q Financial Statement

#000180276821000040 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $585.8M $538.4M
YoY Change 8.8% 15.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $48.59M $50.70M
YoY Change -4.17% 98.05%
% of Gross Profit
Research & Development $90.50M $5.096M
YoY Change 1675.9% -77.55%
% of Gross Profit
Depreciation & Amortization $5.796M $5.800M
YoY Change -0.07% 0.0%
% of Gross Profit
Operating Expenses $90.50M $5.096M
YoY Change 1675.9% -77.55%
Operating Profit $303.1M $510.6M
YoY Change -40.64% -4.12%
Interest Expense $44.33M $31.44M
YoY Change 40.97% -54.29%
% of Operating Profit 14.63% 6.16%
Other Income/Expense, Net -$81.26M $113.7M
YoY Change -171.47% -222.94%
Pretax Income $221.8M $624.3M
YoY Change -64.47% 41.87%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $101.9M $290.6M
YoY Change -64.93% -28.94%
Net Earnings / Revenue 17.4% 53.98%
Basic Earnings Per Share $0.24 $0.79
Diluted Earnings Per Share $0.24 $0.79
COMMON SHARES
Basic Shares Outstanding 428.2M shares 370.0M shares
Diluted Shares Outstanding 607.2M shares 370.0M shares

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.868B $1.596B
YoY Change 17.01%
Cash & Equivalents $1.801B $1.553B
Short-Term Investments $67.02M $43.50M
Other Short-Term Assets $8.945M $14.40M
YoY Change -37.87%
Inventory
Prepaid Expenses
Receivables $59.66M $32.00M
Other Receivables $13.84M $5.000M
Total Short-Term Assets $2.776B $2.784B
YoY Change -0.29%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $473.1M $439.8M
YoY Change 7.55%
Other Assets $4.515M $4.891M
YoY Change -7.69%
Total Long-Term Assets $14.96B $13.21B
YoY Change 13.25%
TOTAL ASSETS
Total Short-Term Assets $2.776B $2.784B
Total Long-Term Assets $14.96B $13.21B
Total Assets $17.73B $15.99B
YoY Change 10.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.187M $24.00M
YoY Change -61.72%
Accrued Expenses $126.7M $110.0M
YoY Change 15.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $255.1M $270.0M
YoY Change -5.53%
LONG-TERM LIABILITIES
Long-Term Debt $7.091B $5.812B
YoY Change 22.0%
Other Long-Term Liabilities $110.0M
YoY Change
Total Long-Term Liabilities $7.091B $5.922B
YoY Change 19.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $255.1M $270.0M
Total Long-Term Liabilities $7.091B $5.922B
Total Liabilities $7.346B $6.192B
YoY Change 18.63%
SHAREHOLDERS EQUITY
Retained Earnings $2.321B $1.807B
YoY Change 28.43%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.685M $2.155M
YoY Change 24.59%
Treasury Stock Shares
Shareholders Equity $5.793B $4.452B
YoY Change
Total Liabilities & Shareholders Equity $17.73B $15.99B
YoY Change 10.89%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $101.9M $290.6M
YoY Change -64.93% -28.94%
Depreciation, Depletion And Amortization $5.796M $5.800M
YoY Change -0.07% 0.0%
Cash From Operating Activities $469.8M $508.9M
YoY Change -7.69% 21.46%
INVESTING ACTIVITIES
Capital Expenditures -$1.336B -$802.5M
YoY Change 66.48% -3619.74%
Acquisitions
YoY Change
Other Investing Activities $490.5M -$202.1M
YoY Change -342.71% -65.89%
Cash From Investing Activities -$845.5M -$1.005B
YoY Change -15.84% 63.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.034B -357.4M
YoY Change -389.39% 27.32%
NET CHANGE
Cash From Operating Activities 469.8M 508.9M
Cash From Investing Activities -845.5M -1.005B
Cash From Financing Activities 1.034B -357.4M
Net Change In Cash 658.5M -853.1M
YoY Change -177.19% 78.85%
FREE CASH FLOW
Cash From Operating Activities $469.8M $508.9M
Capital Expenditures -$1.336B -$802.5M
Free Cash Flow $1.806B $1.311B
YoY Change 37.7% 230.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001802768
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39329
dei Entity Registrant Name
EntityRegistrantName
Royalty Pharma plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1535773
CY2021Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
579746000 USD
dei Entity Address Address Line1
EntityAddressAddressLine1
110 East 59th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
883-0200
dei Security12b Title
Security12bTitle
Class A ordinary shares, par value $0.0001
dei Trading Symbol
TradingSymbol
RPRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1800808000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1008680000 USD
CY2021Q3 us-gaap Trading Securities Debt
TradingSecuritiesDebt
245745000 USD
CY2020Q4 us-gaap Trading Securities Debt
TradingSecuritiesDebt
983279000 USD
CY2020Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
298689000 USD
CY2020Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
587193000 USD
CY2021Q3 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
59657000 USD
CY2020Q4 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
33155000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
67016000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
69984000 USD
CY2021Q3 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
13844000 USD
CY2020Q4 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
6011000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
8945000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8596000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
2775761000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2696898000 USD
CY2021Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
14014116000 USD
CY2020Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
12368084000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11466000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28666000 USD
CY2021Q3 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
264765000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
188684000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
163016000 USD
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
473051000 USD
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
454936000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4515000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9997000 USD
CY2021Q3 us-gaap Assets
Assets
17732358000 USD
CY2020Q4 us-gaap Assets
Assets
16020286000 USD
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
119135000 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
126366000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9187000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10775000 USD
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
16733000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
42146000 USD
CY2021Q3 rprx Accrued Purchase Obligation Current
AccruedPurchaseObligationCurrent
110000000 USD
CY2020Q4 rprx Accrued Purchase Obligation Current
AccruedPurchaseObligationCurrent
110000000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18600000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
255055000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
307887000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7090669000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5816584000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
7345724000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
6124471000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2020Q4 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2021Q3 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
357720000 shares
CY2021Q3 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
357720000 shares
CY2020Q4 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
316407000 shares
CY2020Q4 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
316407000 shares
CY2021Q3 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 USD
CY2020Q4 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3454218000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2865964000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2320878000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1920635000 USD
CY2021Q3 us-gaap Minority Interest
MinorityInterest
4593564000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
5077036000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
20553000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34395000 USD
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
2685000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2317000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10386634000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9895815000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17732358000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16020286000 USD
CY2021Q3 us-gaap Revenues
Revenues
585773000 USD
CY2020Q3 us-gaap Revenues
Revenues
538399000 USD
us-gaap Revenues
Revenues
1713763000 USD
us-gaap Revenues
Revenues
1550210000 USD
CY2021Q3 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
137837000 USD
CY2020Q3 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
-33792000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
186337000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
101498000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90500000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5096000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96263000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18510000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5796000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5796000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17200000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17262000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
282721000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48588000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50732000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
136665000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
131596000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
27832000 USD
us-gaap Costs And Expenses
CostsAndExpenses
436465000 USD
us-gaap Costs And Expenses
CostsAndExpenses
268866000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
303052000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
510567000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1277298000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1281344000 USD
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2749000 USD
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
13743000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
18532000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
33961000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
44327000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
31444000 USD
us-gaap Interest Expense
InterestExpense
119168000 USD
us-gaap Interest Expense
InterestExpense
119217000 USD
CY2021Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-16972000 USD
CY2020Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-7088000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-21436000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-39886000 USD
CY2021Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-19289000 USD
CY2020Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
160226000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-17980000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
200955000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-14885000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
8246000 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 USD
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
12261000 USD
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1587000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
42896000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
7169000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-793000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23337000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-858000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-81256000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
113687000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-89768000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
53982000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
221796000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
624254000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1187530000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1335326000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
221796000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
624254000 USD
us-gaap Profit Loss
ProfitLoss
1187530000 USD
us-gaap Profit Loss
ProfitLoss
1335326000 USD
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
119867000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
333622000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
575706000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
531380000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
101929000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
290632000 USD
us-gaap Net Income Loss
NetIncomeLoss
611824000 USD
us-gaap Net Income Loss
NetIncomeLoss
803946000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
0 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
0 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
0 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
4066000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2575000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7571000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8574000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
67245000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
11756000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
40545000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14331000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7571000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-31971000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
71311000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
-6000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
3768000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
-14112000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
15064000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-8331000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3803000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-17859000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
56247000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
93598000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
294435000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
593965000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
860193000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.88
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.88
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
428230000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
369999000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
409253000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
367753000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607174000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
370002000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607152000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
367756000 shares
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10405365000 USD
CY2021Q3 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
6030000 USD
CY2021Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
159714000 USD
CY2021Q3 us-gaap Dividends Cash
DividendsCash
73017000 USD
CY2021Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 USD
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
505000 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
221796000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2575000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
11756000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10386634000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394961000 USD
CY2020Q3 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
2105000 USD
CY2020Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
175348000 USD
CY2020Q3 us-gaap Dividends Cash
DividendsCash
54885000 USD
CY2020Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
848000 USD
CY2020Q3 rprx Stockholders Equity Value Effect Of Exchange And Reallocation
StockholdersEquityValueEffectOfExchangeAndReallocation
-858000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
624254000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7571000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9798648000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9895815000 USD
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
20803000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
475901000 USD
us-gaap Dividends Cash
DividendsCash
211581000 USD
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1939000 USD
us-gaap Profit Loss
ProfitLoss
1187530000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8574000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
40545000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10386634000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6141438000 USD
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
1450070000 USD
rprx Noncontrolling Interest Transfers Of Interests
NoncontrollingInterestTransfersOfInterests
0 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
865032000 USD
rprx Stock Issued During Period Value Issued For Registration
StockIssuedDuringPeriodValueIssuedForRegistration
63000 USD
us-gaap Profit Loss
ProfitLoss
624885000 USD
rprx Stock Issued During Period Value Issued To Partnerships
StockIssuedDuringPeriodValueIssuedToPartnerships
1000 USD
rprx Stockholders Equity Value Effect Of Exchange And Reallocation
StockholdersEquityValueEffectOfExchangeAndReallocation
-1000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1908474000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4588000 USD
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 USD
us-gaap Dividends Cash
DividendsCash
54885000 USD
us-gaap Profit Loss
ProfitLoss
710441000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
67245000 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
4066000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9798648000 USD
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1733147000 USD
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1549211000 USD
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
113133000 USD
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
104131000 USD
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
27469000 USD
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
12614000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
28213000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
36041000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3004000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
7476000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
34660000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
45252000 USD
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
34660000 USD
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
0 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
16093000 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
35448000 USD
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
6263000 USD
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
18510000 USD
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
90000000 USD
rprx Payments For Upfront Development Stage Funding
PaymentsForUpfrontDevelopmentStageFunding
0 USD
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
135272000 USD
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
129382000 USD
us-gaap Interest Paid Net
InterestPaidNet
129759000 USD
us-gaap Interest Paid Net
InterestPaidNet
102429000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1527579000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1468956000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
523000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
15084000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
28320000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
29262000 USD
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
100013000 USD
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
50000000 USD
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
115957000 USD
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
52755000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
46875000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
755668000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1095259000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1493135000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
609604000 USD
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
2019768000 USD
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
1377085000 USD
rprx Payments For Milestones
PaymentsForMilestones
18600000 USD
rprx Payments For Milestones
PaymentsForMilestones
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1318634000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1926918000 USD
rprx Payments For Distributions To Shareholders And Unitholders
PaymentsForDistributionsToShareholdersAndUnitholders
0 USD
rprx Payments For Distributions To Shareholders And Unitholders
PaymentsForDistributionsToShareholdersAndUnitholders
285353000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
363624000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
400893000 USD
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
119507000 USD
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
74231000 USD
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
211581000 USD
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
54885000 USD
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
6083000 USD
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
6221000 USD
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
11524000 USD
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
29985000 USD
rprx Repayments Of Long Term Debt Scheduled Payments
RepaymentsOfLongTermDebtScheduledPayments
0 USD
rprx Repayments Of Long Term Debt Scheduled Payments
RepaymentsOfLongTermDebtScheduledPayments
94200000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
11116196000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1272533000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
11891030000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
12245000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
46564000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1909651000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
583183000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1764565000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
792128000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1306603000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1008680000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
246199000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1800808000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1552802000 USD
us-gaap Use Of Estimates
UseOfEstimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.
CY2020Q3 rprx Number Of Noncontrolling Interests Created
NumberOfNoncontrollingInterestsCreated
2 partnership
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Certain prior period amounts have been reclassified to conform to the current period presentation.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of September 30, 2021 and December 31, 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex.
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
192097000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
63603000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
255700000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
67016000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
188684000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
255700000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145647000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
87353000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
233000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
69984000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
163016000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
233000000 USD
CY2021Q2 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
600000000 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
35400000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
45300000 USD
CY2021Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-19300000 USD
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-30000000 USD
CY2020Q3 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-46900000 USD
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-98600000 USD
CY2021Q3 us-gaap Notes Receivable Gross
NotesReceivableGross
16022302000 USD
CY2021Q3 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
1128065000 USD
CY2021Q3 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
14894237000 USD
CY2021Q3 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
300375000 USD
CY2021Q3 us-gaap Notes Receivable Net
NotesReceivableNet
14593862000 USD
CY2020Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
14219101000 USD
CY2020Q4 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
940107000 USD
CY2020Q4 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
13278994000 USD
CY2020Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
323717000 USD
CY2020Q4 us-gaap Notes Receivable Net
NotesReceivableNet
12955277000 USD
CY2020Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
1263824000 USD
rprx Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense
FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
611835000 USD
rprx Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense
FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
402155000 USD
us-gaap Financing Receivable Change In Present Value Expense Reversal
FinancingReceivableChangeInPresentValueExpenseReversal
-21721000 USD
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
-23343000 USD
CY2021Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
1428440000 USD
CY2020Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
323700000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
594750000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11466000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
577550000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28666000 USD
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
209331000 USD
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
183416000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
7090669000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5816584000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7090669000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5816584000 USD
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.17
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
211600000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2400000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4700000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2021Q3 us-gaap Profit Loss
ProfitLoss
221796000 USD
us-gaap Profit Loss
ProfitLoss
1187530000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
101929000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
611824000 USD
CY2021Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
42592000 USD
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
294098000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
144521000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
905922000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
428230000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
409253000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
178942000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
197881000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
18000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607174000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607152000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.49
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
CY2020Q3 us-gaap Profit Loss
ProfitLoss
624254000 USD
us-gaap Profit Loss
ProfitLoss
1335326000 USD
CY2020Q3 rprx Net Income Loss Attributable To Parent Prior To Offering
NetIncomeLossAttributableToParentPriorToOffering
0 USD
rprx Net Income Loss Attributable To Parent Prior To Offering
NetIncomeLossAttributableToParentPriorToOffering
479842000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
290632000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
324104000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
369999000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
367753000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
370002000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
367756000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.88
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.88
us-gaap Profit Loss
ProfitLoss
1187530000 USD
us-gaap Profit Loss
ProfitLoss
1335326000 USD
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1538871000 USD
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1435536000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
186337000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
101498000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17200000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17262000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
14822000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6869000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-21436000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-39886000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-17980000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
200955000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
18532000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
33961000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
28213000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
36041000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-358000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-30272000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1939000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4588000 USD
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
40545000 USD
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
0 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
8246000 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 USD
rprx Gain Loss On Derivative Financial Instruments
GainLossOnDerivativeFinancialInstruments
16093000 USD
rprx Gain Loss On Derivative Financial Instruments
GainLossOnDerivativeFinancialInstruments
34952000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3263000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8163000 USD
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1733147000 USD
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1549211000 USD
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
26502000 USD
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
-1153000 USD
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
7833000 USD
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
-852000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
473000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-31835000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2138000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11404000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-25413000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1527579000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1468956000 USD
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
0 USD
us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
303679000 USD
us-gaap Transfer Of Investments
TransferOfInvestments
0 USD
us-gaap Transfer Of Investments
TransferOfInvestments
5700000 USD
rprx Settlements With Equity Method Investments
SettlementsWithEquityMethodInvestments
0 USD
rprx Settlements With Equity Method Investments
SettlementsWithEquityMethodInvestments
220000000 USD
rprx Accrued Purchase Obligation Equity Investment
AccruedPurchaseObligationEquityInvestment
0 USD
rprx Accrued Purchase Obligation Equity Investment
AccruedPurchaseObligationEquityInvestment
1103774000 USD
rprx Milestone Payment Accrued But Not Paid
MilestonePaymentAccruedButNotPaid
0 USD
rprx Milestone Payment Accrued But Not Paid
MilestonePaymentAccruedButNotPaid
1177000 USD
CY2021Q3 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
119135000 USD
CY2020Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
126366000 USD

Files In Submission

Name View Source Status
0001802768-21-000040-index-headers.html Edgar Link pending
0001802768-21-000040-index.html Edgar Link pending
0001802768-21-000040.txt Edgar Link pending
0001802768-21-000040-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
rprx-20210930.htm Edgar Link pending
rprx-20210930.xsd Edgar Link pending
rprx-20210930ex311.htm Edgar Link pending
rprx-20210930ex312.htm Edgar Link pending
rprx-20210930ex32.htm Edgar Link pending
rprx-20210930_cal.xml Edgar Link unprocessable
rprx-20210930_def.xml Edgar Link unprocessable
rprx-20210930_htm.xml Edgar Link completed
rprx-20210930_lab.xml Edgar Link unprocessable
rprx-20210930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending